Lead Selection and Clinical Translatability


Selecting the right candidate for development is a crucial step in the drug discovery
process as many late stage failures are attributed to lack of efficacy or unforeseen
adverse events (not detected in routine GLP tox). New approaches are needed to
interrogate compound effects on relevant disease and toxicity mechanisms to more fully
understand the complete range of pharmacological effects that are currently not
addressed by current conventional assay systems. Having insight into the full spectrum
of compound effects during the lead optimization stage, prior to candidate selection, can
offer a more informed choice on which compounds to advance (and what biomarker to
accompany it).